The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AKT inhibition as a therapeutic strategy to constrain histological transdifferentiation in EGFR-mutant lung adenocarcinoma.
 
Alvaro Quintanal-Villalonga
Honoraria - AstraZeneca
 
Hirokazu Taniguchi
No Relationships to Disclose
 
Yingqian A. Zhan
No Relationships to Disclose
 
Jacklynn V. Egger
No Relationships to Disclose
 
Umesh Bhanot
No Relationships to Disclose
 
Juan Qiu
No Relationships to Disclose
 
Elisa de Stanchina
No Relationships to Disclose
 
Natasha Rekhtman
No Relationships to Disclose
 
Brian Houck-Loomis
No Relationships to Disclose
 
Richard P. Koche
No Relationships to Disclose
 
Triparna Sen
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bridge Medicines; Daiichi Sankyo/UCB Japan; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Jazz Pharmaceuticals; Kowa; Merck; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)